Efficacy Of Bupropion Sr On Reducing Craving In Smoking Cessation

Authors: Fiedler-Kelly J, Grasela TH, Glover ED, Sachs DPL, Johnston JA
Conference: CINP Congress
Keywords: adult, cessation, cigarettes, Emax, Fagerstrom, logit transform, nictotine, NONMEM, patch, predicted odds, proportional-odds model, psychotherapeutic agents, rating, time course
Division: Clinical Pharmacology and Pharmacometrics (CPP)

Introduction

Bupropion HCl sustained release (Bup SR, ZybanTM) is the first non-nicotine treatment proven to be safe and effective for smoking cessation. Clinical studies have demonstrated that when used in combination with a behavioral support program, Bup SR produces increases in smoking cessation rates relative to placebo, and that the efficacy of Bup SR is greater than that seen with the Habitrol® nicotine patch. Hurt, et al., reported the results of a dose-response study showing a clear dose response for smoking cessation. In the same report, an analysis of composite withdrawal symptoms, including craving, failed to demonstrate a treatment effect.(1)

International College of Neuro-Psychopharmacology (CINP) Congress; Glasgow, Scotland; July 1998

By Jill Fiedler-Kelly, Thaddeus H. Grasela, Elbert D. Glover, David P.L. Sachs, J. Andrew Johnston